Current Cardiology Reports

, 13:559 | Cite as

CETP Inhibition: Does the Future Look Promising?

Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor)

Abstract

Based on epidemiologic studies conducted throughout the world, it is established that there is an inverse relationship between high-density lipoprotein cholesterol (HDL-C) and risk for coronary artery disease (CAD). The incidence of low HDL-C is high and increasing throughout the world. A variety of pharmacologic approaches are being developed to therapeutically modulate serum levels of HDL-C. One controversial approach to this is the use of molecules that inhibit the activity of cholesteryl ester transfer protein (CETP), an enzyme involved in neutral lipid transfer between lipoproteins. The inhibition of CETP can lead to substantial elevations in HDL-C. Based on a number of considerations, including the complex relationship between loss of function mutations in CETP and risk for CAD and the clinical experience with torcetrapib, it is difficult to predict if CETP inhibition will be associated with reductions in rates of atherosclerosis disease progression and risk for cardiovascular events.

Keywords

Apolipoprotein A-I Apolipoprotein B Atherosclerosis Cholesterol Cholesteryl ester transfer protein CETP Coronary artery disease High-density lipoprotein Low-density lipoprotein receptor Reverse cholesterol transport Polymorphism Scavenger receptor BI Very low density lipoprotein 

Clinical Trial Acronyms

AIM-HIGH

Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes

dal-HEART

Dalcetrapib HDL Evaluation, Atherosclerosis, and Reverse Cholesterol Transport Program

DEFINE

Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib

ILLUMINATE

Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events

ILLUSTRATE

Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation

HPS2-THRIVE

Treatment of High-Density Lipoprotein to Reduce the Incidence of Vascular Events

RADIANCE

Rating Atherosclerotic Disease Change by Imaging with a New CEPT Inhibitor

REGRESS

Regression Growth Evaluation Statin Study

REVEAL HPS-3 TIMI-55

Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification

Notes

Disclosure

Conflicts of interest: P.P. Toth: has been a consultant for Amgen, Abbott, Genentech, and Merck; and has received payment for development of educational presentations including speakers’ bureaus from Abbott, GlaxoSmithKline, Merck, Kowa, Boehringer-Ingelheim, Takeda, and AstraZeneca.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol 1988; 4 Suppl A:5A-10A.Google Scholar
  2. 2.
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108–13.PubMedCrossRefGoogle Scholar
  4. 4.
    • Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117:746–56. These investigators demonstrated that the HDL proteosome is characterized by over 75 different enzymes, apolipoproteins, globulins, and other proteins that impact HDL functionality.PubMedCrossRefGoogle Scholar
  5. 5.
    Toth PP. Activation of intracellular signaling systems by high-density lipoproteins. J Clin Lipidol. 2010;4:376–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Brewer H. High-density lipoproetins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscl Thromb Vascul Biol. 2004;24:387–91.CrossRefGoogle Scholar
  7. 7.
    •• Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127–35. These investigators demonstrated in convincing fashion that HDL functionality as measured by capacity for driving RCT impacts risk for CHD more than measurements of HDL-C.PubMedCrossRefGoogle Scholar
  8. 8.
    Toth PP, Potter D, Ming E. Abstract 12055: Prevalence of Lipid Abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006. Circulation. 2010;122:A12055.Google Scholar
  9. 9.
    Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21:1927–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Aguilar-Salinas CA, Olaiz G, Valles V, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42:1298–307.PubMedGoogle Scholar
  11. 11.
    Li Z, Yang R, Xu G, Xia T. Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing. Clin Chem. 2005;51:144–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRefGoogle Scholar
  13. 13.
    Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285:2486–97.CrossRefGoogle Scholar
  14. 14.
    Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117:2458–66.PubMedCrossRefGoogle Scholar
  15. 15.
    Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. Jama. 2007;297:499–508.PubMedCrossRefGoogle Scholar
  16. 16.
    Brown B, Zhao X, Cheung M. Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. J Clin Lipidol. 2007;1:88–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Goldenberg I, Goldbourt U, Boyko V, et al. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol. 2006;97:466–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Cui Y, Watson DJ, Girman CJ, et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol. 2009;104:829–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–91.PubMedCrossRefGoogle Scholar
  20. 20.
    • The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011; 161:471–477 e2. This much awaited trial was recently terminated by the US National Heart, Lung, and Blood Institute due to futility. No separation of outcome curves between treatment groups could be discerned. Because of these findings, the role of niacin therapy in patients with low serum levels of HDL-C has been called into question. Another trial testing the therapeutic value of niacin therapy in patients with low HDL-C and CAD (HPS2-THRIVE) remains underway.Google Scholar
  21. 21.
    Toth PP. Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease. Curr Cardiol Rep. 2010;12:481–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Qiu X, Mistry A, Ammirati MJ, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007;14:106–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053–9.PubMedCrossRefGoogle Scholar
  25. 25.
    •• Thompson A, Di Angelantonio E, Sarwar N et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299:2777–88. Important meta-analysis demonstrating that loss-of-function mutations in CETP do correlate with modest reductions in risk for CHD.PubMedCrossRefGoogle Scholar
  26. 26.
    Brousseau ME, O'Connor Jr JJ, Ordovas JM, et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol. 2002;22:1148–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 2000;101:1907–12.PubMedGoogle Scholar
  28. 28.
    Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, et al. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation. 2000;102:2197–203.PubMedGoogle Scholar
  29. 29.
    Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. The effect of cholesteryl ester transfer protein -629 C-> A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab. 2005;90:4198–204.PubMedCrossRefGoogle Scholar
  30. 30.
    Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29:2792–9.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Vasan RS, Pencina MJ, Robins SJ et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009; 120:2414–20. This analysis performed in the world's most important epidemiologic cohort demonstrates an inverse relationship between CETP activity and risk for CHD-related events.PubMedCrossRefGoogle Scholar
  32. 32.
    Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506–14.PubMedCrossRefGoogle Scholar
  34. 34.
    Kastelein JJ, van Leuven SI, Burgess L et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. N Engl J Med 2007.Google Scholar
  35. 35.
    Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.PubMedCrossRefGoogle Scholar
  37. 37.
    Sirtori CR, Mombelli G. Cholesteryl ester transfer protein antagonism by drugs–a poor choice. Clin Chem. 2010;56:1550–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465–73.PubMedCrossRefGoogle Scholar
  40. 40.
    Connelly MA, Parry TJ, Giardino EC, et al. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J Cardiovasc Pharmacol. 2010;55:459–68.PubMedGoogle Scholar
  41. 41.
    Xing Y, Cohen A, Rothblat G, Sankaranarayanan S, Weibel G, Royer L, et al. Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2). Endocrinology. 2011;152(3):751–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol. 2009;104:82–91.PubMedCrossRefGoogle Scholar
  43. 43.
    Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J. 2010;31:480–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15.PubMedCrossRefGoogle Scholar
  45. 45.
    Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51:2739–52.PubMedCrossRefGoogle Scholar
  46. 46.
    •• Niesor EJ, Magg C, Ogawa N et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51:3443–54. Elegant experimental demonstration of how dalcetrapib potentiates the regeneration of poorly lipdated HDL particles (pre-β HDL) and increases rates of RCT.PubMedCrossRefGoogle Scholar
  47. 47.
    Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896–901 e3.PubMedCrossRefGoogle Scholar
  48. 48.
    Kastelein JJ, Duivenvoorden R, Deanfield J, et al. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin. 2011;27:141–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Director of Preventive CardiologySterling Rock Falls ClinicSterlingUSA
  2. 2.University of Illinois School of MedicinePeoriaUSA

Personalised recommendations